CN115804803B - Composition for inhibiting helicobacter pylori and preparation method thereof - Google Patents
Composition for inhibiting helicobacter pylori and preparation method thereof Download PDFInfo
- Publication number
- CN115804803B CN115804803B CN202211629293.0A CN202211629293A CN115804803B CN 115804803 B CN115804803 B CN 115804803B CN 202211629293 A CN202211629293 A CN 202211629293A CN 115804803 B CN115804803 B CN 115804803B
- Authority
- CN
- China
- Prior art keywords
- parts
- helicobacter pylori
- litsea
- extracting
- ethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a composition for inhibiting helicobacter pylori and a preparation method thereof, wherein the composition comprises the following raw materials in parts by weight: 110 to 160 parts of royal jelly, 100 to 150 parts of eucalyptus honey, 110 to 150 parts of caltrop, 100 to 150 parts of berk nut, 90 to 170 parts of acanthopanax sessiliflorus, 110 to 150 parts of purple daisy, 110 to 150 parts of lithocarpus litsea, and 90 to 170 parts of gymnema sylvestre. The composition provided by the invention screens the proportion of each component through a large number of experiments, is scientific and reasonable, extracts active ingredients which play a role in inhibiting helicobacter pylori from each raw material through the formula process defined by the invention, and greatly improves the utilization rate and bioavailability of the raw material.
Description
Technical Field
The invention relates to the technical field of health-care food and medicine compositions, in particular to a composition for inhibiting helicobacter pylori and a preparation method thereof.
Background content
At present, the world health organization recommends a triple therapy based on clarithromycin for the treatment of helicobacter pylori infection: treatment with proton pump inhibitors, clarithromycin in combination with amoxicillin or metronidazole or tinidazole was for 14 days. However, proton pump inhibitors can adversely affect the intestinal mucosa, increase intestinal mucosa permeability, and decrease intestinal barrier function. Clarithromycin and amoxicillin are antibiotics, which break the steady state balance of intestinal flora. Metronidazole or tinidazole both have different degrees of irritating adverse effects on the stomach. At present, with the wide use of triple schemes and other schemes, the drug resistance rate of helicobacter pylori is higher and higher, and the eradication rate is reduced.
Helicobacter pylori is a gram-negative bacterium which has extremely strong viability and can survive in the strongly acidic environment in the stomach, and is the only bacterium which can survive in the stomach currently found. Therefore, the research in this respect has been conducted, and it is of great importance to find a composition for inhibiting helicobacter pylori which is excellent in effect. Although most herbs have antibacterial effects, fewer herbs with specific helicobacter pylori inhibition function are provided, and the active ingredients for inhibiting helicobacter pylori are not clearly known, so that most formulas for inhibiting helicobacter pylori are all herbs, but only a small part of active ingredients in all herbal raw materials are truly used for inhibiting helicobacter pylori, and the herbs need to be used in a large amount to be effective, so that the problems of raw material resource waste and large-dose inconvenient taking of consumers are easily caused. Thus, there is an urgent need in the art to develop products that specifically inhibit the active ingredients of helicobacter pylori by herbs.
Disclosure of Invention
Aiming at the problem that the effect of inhibiting helicobacter pylori is not clear in herbaceous plants, the invention screens the raw materials for inhibiting helicobacter pylori according to more than 100 herbaceous plants, and then extracts and researches the screened raw materials with different effects of different reagents, so as to finally provide the composition for effectively inhibiting helicobacter pylori. In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
a composition for inhibiting helicobacter pylori comprises the following raw materials in parts by weight: 110 to 160 parts of royal jelly, 100 to 150 parts of eucalyptus honey, 110 to 150 parts of caltrop, 100 to 150 parts of berk nut, 90 to 170 parts of acanthopanax sessiliflorus, 110 to 150 parts of purple daisy, 110 to 150 parts of lithocarpus litsea, and 90 to 170 parts of gymnema sylvestre. The preparation of the composition comprises the following steps:
(1) Thawing Lac Regis Apis with water, mixing with Eucalyptus Mel, and lyophilizing to obtain powder.
(2) Pulverizing fructus Tribuli, berhard Hu Taoguo, and radix Acanthopanacis Senticosi, extracting with mixed solvent of ethanol water solution and ethylene glycol dimethyl ether water solution, filtering, extracting the filtrate with N-N-dimethylformamide water solution, separating with ultrafiltration membrane, concentrating under reduced pressure to remove solvent, and drying to obtain extract powder.
(3) Pulverizing Echinacea purpurea, litsea coreana and Gymnema Yunnanense Tsiang, extracting with ethanol water solution and ethylene glycol monoethyl ether, filtering, extracting the filtrate with N-N-dimethylformamide water solution, separating with ultrafiltration membrane, concentrating under reduced pressure to remove solvent, and drying to obtain extract powder.
(4) Mixing the above processed powders.
Preferably, the helicobacter pylori inhibiting composition comprises the following raw materials in parts by weight: 120-140 parts of royal jelly, 110-140 parts of eucalyptus honey, 120-140 parts of caltrop, 120-140 parts of berk nut, 120-150 parts of acanthopanax sessiliflorus, 120-140 parts of purple daisy, 120-140 parts of lithocarpus litsea, and 130-150 parts of gymnema sylvestre.
Preferably, the helicobacter pylori inhibiting composition comprises the following raw materials in parts by weight: 110 to 130 parts of royal jelly, 100 to 130 parts of eucalyptus honey, 120 to 150 parts of caltrop, 120 to 150 parts of berk nut, 90 to 140 parts of acanthopanax sessiliflorus, 110 to 130 parts of purple daisy, 120 to 150 parts of lithocarpus litsea, and 130 to 170 parts of gymnema sylvestre.
Preferably, the helicobacter pylori inhibiting composition comprises the following raw materials in parts by weight: 130-160 parts of royal jelly, 130-150 parts of eucalyptus honey, 110-130 parts of caltrop, 100-130 parts of berk nut, 140-170 parts of acanthopanax sessiliflorus, 120-150 parts of purple daisy, 110-130 parts of lithocarpus litsea, and 90-140 parts of gymnema sylvestre.
Preferably, in the step (2), the volume fraction of the ethanol aqueous solution is 80% -100%, the volume fraction of the ethylene glycol dimethyl ether aqueous solution is 45% -75%, and the volume ratio of the ethanol aqueous solution to the ethylene glycol dimethyl ether aqueous solution is (5-8): (1-3), the ratio of the extraction liquid to the solution is 1: (6-8), the extraction temperature is 25-35 ℃, the extraction time is 1-2 h, the volume fraction of the N-N-dimethylformamide aqueous solution is 60-80%, and the extraction liquid-liquid ratio (namely the volume ratio of the N-N-dimethylformamide aqueous solution to the filtrate) is 1: (1.5-2.0), extracting at normal temperature for 2-3 h, wherein the molecular weight cut-off of the ultrafiltration membrane is 30000-50000.
Preferably, in the step (3), the volume fraction of the ethanol aqueous solution is 80% -90%, the volume fraction of the ethylene glycol monoethyl ether is 30% -60%, and the volume ratio of the ethanol aqueous solution to the ethylene glycol monoethyl ether is (2-3): 1, the ratio of the extraction liquid to the liquid is 1: (6-8), the extraction temperature is 30-40 ℃, the extraction time is 1-2 h, the volume fraction of the N-N-dimethylformamide aqueous solution is 60-80%, and the extraction liquid-liquid ratio (namely the volume ratio of the N-N-dimethylformamide aqueous solution to the filtrate) is 1: (1.5-2.0), the extraction time is 2-3 h, and the molecular weight cut-off of the ultrafiltration membrane is 20000-50000.
The invention also provides application of the composition in preparing health-care food and medicine for resisting helicobacter pylori.
Compared with the prior art, the invention has the beneficial effects that:
aiming at the problem that the active ingredients of the existing herbaceous plants for inhibiting helicobacter pylori are not clear, the proportion of each component is screened through a large number of experiments, the invention is scientific and reasonable, the active ingredients for inhibiting helicobacter pylori in the raw materials of caltrop, berhard Hu Taoguo, acanthopanax sessiliflorus, purple daisy, lithocarpus litsea, and gymnema sylvestre are extracted through the formula process defined by the invention, 100g of the raw materials are concentrated to less than 1g of the real active ingredients, and the utilization rate and bioavailability of the raw materials are greatly improved. And the whole preparation process has high automation degree and high preparation efficiency.
Detailed Description
The following description of the technical solutions in the embodiments of the present invention will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
A composition for inhibiting helicobacter pylori comprises the following raw materials in parts by weight: 110 parts of royal jelly, 100 parts of eucalyptus honey, 150 parts of caltrop, 120 parts of berk nut, 90 parts of acanthopanax sessiliflorus, 110 parts of purple daisy, 140 parts of lithocarpus litsea, and 150 parts of gymnema sylvestre.
Wherein the preparation of the composition comprises the steps of:
(1) Thawing Lac Regis Apis with water, mixing with Eucalyptus Mel, and lyophilizing to obtain powder.
(2) Pulverizing fructus Tribuli, berhard Hu Taoguo, and radix Acanthopanacis Senticosi, respectively preparing 80% (volume fraction) ethanol water solution and 60% (volume fraction) ethylene glycol dimethyl ether water solution, preparing into mixed solvent at a volume ratio of 5:1, adding pulverized powder into the mixed solvent at a feed liquid ratio of 1:6, extracting at 25deg.C for 1 hr, filtering, and mixing the filtrate with a liquid-liquid ratio (i.e. volume ratio of N-N-dimethylformamide water solution to filtrate) of 1:1.5 adding 60% (volume fraction) N-N-dimethylformamide water solution, extracting at normal temperature for 2 hr, separating with ultrafiltration membrane with molecular weight cut-off of 30000-50000, concentrating under reduced pressure to remove solvent, and drying to obtain extract powder 2.6 parts.
(3) Crushing the purple daisy, the lithocarpus litsea and the gymnema sylvestre, preparing 90 percent (volume fraction) of ethanol aqueous solution and 50 percent (volume fraction) of ethylene glycol monoethyl ether, preparing a mixed solvent according to a volume ratio of 2:1, adding the crushed powder into the mixed solvent according to a feed liquid ratio of 1:8, extracting for 1h at 30 ℃, filtering, and then mixing the filtrate according to a liquid-liquid ratio of (namely, the volume ratio of the N-N-dimethylformamide aqueous solution to the filtrate) 1:1.8 adding 70% (volume fraction) N-N-dimethylformamide water solution, extracting at normal temperature for 3 hr, separating with ultrafiltration membrane with molecular weight cut-off of 20000-50000, concentrating under reduced pressure to remove solvent, and drying to obtain extract powder 3.9 parts.
(4) Mixing the above processed powders.
Example 2
A composition for inhibiting helicobacter pylori comprises the following raw materials in parts by weight: 120 parts of royal jelly, 110 parts of eucalyptus honey, 130 parts of caltrop, 150 parts of berk nut, 120 parts of acanthopanax sessiliflorus, 130 parts of purple daisy, 120 parts of lithocarpus litsea, and 170 parts of gymnema sylvestre.
Wherein the preparation of the composition comprises the steps of:
(1) Thawing Lac Regis Apis with water, mixing with Eucalyptus Mel, and lyophilizing to obtain powder.
(2) Pulverizing fructus Tribuli, berhard Hu Taoguo, and radix Acanthopanacis Senticosi, respectively preparing 85% (volume fraction) ethanol water solution and 45% (volume fraction) ethylene glycol dimethyl ether water solution, preparing into mixed solvent at a volume ratio of 5:3, adding pulverized powder into the mixed solvent at a feed liquid ratio of 1:6.5, extracting at 30deg.C for 2 hr, filtering, and mixing filtrate with a liquid-liquid ratio (i.e. volume ratio of N-N-dimethylformamide water solution to filtrate) of 1:2.0 adding 80% (volume fraction) N-N-dimethylformamide water solution, extracting at normal temperature for 3 hr, separating with ultrafiltration membrane with molecular weight cut-off of 30000-50000, concentrating under reduced pressure to remove solvent, and drying to obtain extract powder 3.5 parts.
(3) Crushing the purple daisy, the lithocarpus litsea and the gymnema sylvestre, preparing a mixed solvent of 80 percent (volume fraction) of ethanol aqueous solution and 30 percent (volume fraction) of ethylene glycol monoethyl ether according to the volume ratio of 3:1, adding the crushed powder into the mixed solvent according to the feed liquid ratio of 1:6.5, extracting for 2 hours at 35 ℃, filtering, and then mixing the filtrate according to the liquid-liquid ratio (namely the volume ratio of the N-N-dimethylformamide aqueous solution to the filtrate) of 1:1.7 adding 60% (volume fraction of filtrate) N-N-dimethylformamide water solution, extracting at normal temperature for 2 hr, separating with ultrafiltration membrane with molecular weight cut-off of 20000-50000, concentrating under reduced pressure to remove solvent, and drying to obtain extract powder 3.6 parts.
(4) Mixing the above processed powders.
Example 3
A composition for inhibiting helicobacter pylori comprises the following raw materials in parts by weight: 130 parts of royal jelly, 130 parts of eucalyptus honey, 120 parts of caltrop, 140 parts of berk nut, 140 parts of acanthopanax sessiliflorus, 120 parts of purple daisy, 150 parts of lithocarpus litsea, and 130 parts of gymnema sylvestre.
Wherein the preparation of the composition comprises the steps of:
(1) Thawing Lac Regis Apis with water, mixing with Eucalyptus Mel, and lyophilizing to obtain powder.
(2) Pulverizing fructus Tribuli, berhard Hu Taoguo, and radix Acanthopanacis Senticosi, respectively preparing 90% (volume fraction) ethanol water solution and 75% (volume fraction) ethylene glycol dimethyl ether water solution, preparing into mixed solvent at a volume ratio of 7:2, adding pulverized powder into the mixed solvent at a feed liquid ratio of 1:7, extracting at 30deg.C for 1.5 hr, filtering, and mixing filtrate with a liquid-liquid ratio (i.e. volume ratio of N-N-dimethylformamide water solution to filtrate) of 1:1.8 adding 70% (volume fraction) N-N-dimethylformamide water solution, extracting at normal temperature for 2.5 hr, separating with ultrafiltration membrane with molecular weight cut-off of 30000-50000, concentrating under reduced pressure to remove solvent, and drying to obtain extract powder 2.8 parts.
(3) Crushing the purple daisy, the lithocarpus litsea and the gymnema sylvestre, preparing 85 percent (volume fraction) of ethanol aqueous solution and 40 percent (volume fraction) of ethylene glycol monoethyl ether, preparing a mixed solvent according to the volume ratio of 2.5:1, adding the crushed powder into the mixed solvent according to the feed liquid ratio of 1:6, extracting for 1.5 hours at the temperature of 30 ℃, filtering, and then mixing the filtrate according to the liquid-liquid ratio (namely the volume ratio of the N-N-dimethylformamide aqueous solution to the filtrate) of 1:1.5 adding 65% (volume fraction) N-N-dimethylformamide water solution, extracting at normal temperature for 2.5 hr, separating with ultrafiltration membrane with molecular weight cut-off of 20000-50000, concentrating under reduced pressure to remove solvent, and drying to obtain extract powder 3.4 parts.
(4) Mixing the above processed powders.
Example 4
A composition for inhibiting helicobacter pylori comprises the following raw materials in parts by weight: 140 parts of royal jelly, 150 parts of eucalyptus honey, 110 parts of caltrop, 100 parts of berk nut, 170 parts of acanthopanax sessiliflorus, 140 parts of purple daisy, 110 parts of lithocarpus litsea, and 140 parts of gymnema sylvestre.
Wherein the preparation of the composition comprises the steps of:
(1) Thawing Lac Regis Apis with water, mixing with Eucalyptus Mel, and lyophilizing to obtain powder.
(2) Pulverizing fructus Tribuli, berhard Hu Taoguo, and radix Acanthopanacis Senticosi, respectively preparing 95% (volume fraction) ethanol water solution and 55% (volume fraction) ethylene glycol dimethyl ether water solution, preparing into mixed solvent at a volume ratio of 6:2, adding pulverized powder into the mixed solvent at a feed liquid ratio of 1:7.5, extracting at 35deg.C for 1.5 hr, filtering, and mixing the filtrate with a liquid-liquid ratio (i.e. volume ratio of N-N-dimethylformamide water solution to filtrate) of 1:1.7 adding 65% (volume fraction) N-N-dimethylformamide water solution, extracting at normal temperature for 2 hr, separating with ultrafiltration membrane with molecular weight cut-off of 30000-50000, concentrating under reduced pressure to remove solvent, and drying to obtain extract powder 3.0 parts.
(3) Crushing the purple daisy, the lithocarpus litsea and the gymnema sylvestre, preparing 83 percent (volume fraction) of ethanol aqueous solution and 60 percent (volume fraction) of ethylene glycol monoethyl ether, preparing a mixed solvent according to the volume ratio of 2.3:1, adding the crushed powder into the mixed solvent according to the feed liquid ratio of 1:7.5, extracting for 1h at 35 ℃, filtering, and then mixing the filtrate according to the liquid-liquid ratio (namely the volume ratio of the N-N-dimethylformamide aqueous solution to the filtrate) of 1:2.0 adding 80% (volume fraction) N-N-dimethylformamide water solution, extracting at normal temperature for 3 hr, separating with ultrafiltration membrane with molecular weight cutoff of 20000-50000, concentrating under reduced pressure to remove solvent, and drying to obtain extract powder 3.1 parts.
(4) Mixing the above processed powders.
Example 5
A composition for inhibiting helicobacter pylori comprises the following raw materials in parts by weight: 160 parts of royal jelly, 140 parts of eucalyptus honey, 140 parts of caltrop, 130 parts of berk nut, 150 parts of acanthopanax sessiliflorus, 150 parts of purple daisy, 130 parts of lithocarpus litsea, and 90 parts of gymnema sylvestre.
Wherein the preparation of the composition comprises the steps of:
(1) Thawing Lac Regis Apis with water, mixing with Eucalyptus Mel, and lyophilizing to obtain powder.
(2) Pulverizing fructus Tribuli, berhard Hu Taoguo, and radix Acanthopanacis Senticosi, respectively preparing 100% (volume fraction) ethanol water solution and 70% (volume fraction) ethylene glycol dimethyl ether water solution, preparing into mixed solvent at a volume ratio of 8:1, adding pulverized powder into the mixed solvent at a feed liquid ratio of 1:8, extracting at 35deg.C for 2 hr, filtering, and mixing the filtrate with a liquid-liquid ratio (i.e. volume ratio of N-N-dimethylformamide water solution to filtrate) of 1:1.9 adding 75% (volume fraction) N-N-dimethylformamide water solution, extracting at normal temperature for 3 hr, separating with ultrafiltration membrane with molecular weight cut-off of 30000-50000, concentrating under reduced pressure to remove solvent, and drying to obtain extract powder 3.2 parts.
(3) Crushing the purple daisy, the lithocarpus litsea and the gymnema sylvestre, preparing 87 percent (volume fraction) of ethanol aqueous solution and 45 percent (volume fraction) of ethylene glycol monoethyl ether, preparing a mixed solvent according to the volume ratio of 2.7:1, adding the crushed powder into the mixed solvent according to the feed liquid ratio of 1:7, extracting for 1.5 hours at the temperature of 40 ℃, filtering, and then mixing the filtrate according to the liquid-liquid ratio (namely the volume ratio of the N-N-dimethylformamide aqueous solution to the filtrate) of 1:1.6 adding 75% (volume fraction) N-N-dimethylformamide water solution, extracting at normal temperature for 2.5 hr, separating with ultrafiltration membrane with molecular weight cut-off of 20000-50000, concentrating under reduced pressure to remove solvent, and drying to obtain extract powder 2.7 parts.
(4) Mixing the above processed powders.
Comparative example 1
The difference from example 1 is that: fructus Tribuli, berhard Hu Taoguo, radix Acanthopanacis Senticosi, echinacea purpurea, lithocarpus litsea, and Gymnema Yunnanense Tsiang without extraction, and directly mixing with lyophilized Lac Regis Apis and Mel.
Comparative example 2
The difference from example 1 is that: the extraction solvent was changed and 70% (volume fraction) ethanol aqueous solution was used for extraction of Tribulus terrestris, boer's hard Hu Taoguo, acanthopanax sessiliflorus, echinacea, litsea coreana and Gymnema sylvestre, and the other operations were the same as in example 1.
Comparative example 3
The difference from example 1 is that: tribulus terrestris, berhard Hu Taoguo and acanthopanax sessiliflorus are extracted with 80% (volume fraction) ethanol aqueous solution only, and the other procedures are the same as in example 1.
Comparative example 4
The difference from example 1 is that: the procedure of example 1 was repeated except that the second extraction solvent of Echinacea purpurea, litsea coreana, and Gymnema Yunnanense Tsiang was changed to 70% aqueous solution of ethanol.
Comparative example 5
The difference from example 1 is that: all the extracts were subjected to conventional filtration without ultrafiltration membrane for separation, and the other operations were the same as in example 1.
1. The composition of the present invention has an inhibitory effect on helicobacter pylori
Determination of MIC and MBC:
the minimum inhibitory concentration MIC and minimum inhibitory concentration MBC of each example composition and comparative example composition against helicobacter pylori ATCC43504 were determined by double dilution. Each example composition and comparative example composition was double diluted with DMSO to give dilutions of 80 mg/mL, 40 mg/mL, 20mg/mL, 10 mg/mL, 5mg/mL, 2.5 mg/mL, 1.25mg/mL, 0.625mg/mL, 0.3125 mg/mL, 0.1563 mg/mL. mu.L of sterile Brookfield broth, 50. Mu.L of 0.5 Mecania-specific H.pylori solution cultured for 12h and 150. Mu.L of sample were added to each well of a sterile plate 96-well plate. 300. Mu.L of Brookfield broth was used as a blank control, 50. Mu.L of 0.5 Mesona turbidimetric helicobacter pylori solution cultured for 12 hours and 250. Mu.L of sterilized Brookfield broth were used as positive controls, and 3 groups were arranged in parallel.
After 24h microaerophilic incubation at 37 ℃ each well was observed, and the lowest concentration without turbidity compared to the blank was the lowest inhibitory concentration MIC for each sample.
100. Mu.L of the sample from the 96-well plate, which was cultured for 24 hours, was plated on Columbia agar medium. After 72h microaerophilic incubation at 37 ℃, the lowest concentration with a total colony count of less than 5 on the plate was the lowest bactericidal concentration MBC for each sample.
TABLE 1
Note that: + represents a bacterial growth, -represents a sterile growth.
TABLE 2
Note that: + represents a bacterial growth, -represents a sterile growth.
As is apparent from tables 1 and 2 above, the composition of the present invention is effective in inhibiting helicobacter pylori, and at a lower dose, the minimum inhibitory concentration for helicobacter pylori is 0.3125-0.625mg/mL, the minimum inhibitory concentration for helicobacter pylori is 0.625-2.5 mg/mL, and the minimum inhibitory concentration for helicobacter pylori is 2.5-12.5 mg/mL, and the minimum inhibitory concentration for comparative example is 5-40 mg/mL. From the comparison of the results of comparative example 1 and example 1, it is known that the formula process defined by the present invention exerts a better effect of inhibiting helicobacter pylori than the untreated whole grass raw material, indicating that the bioavailability of the raw material is significantly improved by the present invention. From the results of comparative examples 2 to 5, it is understood that the change of any of the treatments of the defined process of the present invention, particularly the change of the extraction solvent, is extremely significantly different in the effect of inhibiting helicobacter pylori.
2. Effect of the composition of the present invention on the negative-working efficacy of helicobacter pylori
The test method comprises the following steps:
(1) preparing bacterial liquid: inoculating helicobacter pylori SS1 strain into a Brookfield agar culture medium, in an anaerobic environment,
culturing at 37deg.C for 3 days, performing gram staining microscopic examination, determining helicobacter pylori by urokinase, peroxide and catalase test, and culturing with Brucella broth for 3 days to obtain bacterial liquid;
(2) molding and testing: wistar rats were subjected to 5 times per week for 5 times in total after each half of male and female rats were subjected to gastric lavage with 5% sodium bicarbonate solution (2 mL/piece of gastric lavage) for 15min and then subjected to gastric lavage with bacterial liquid (1.5 mL/piece of gastric lavage). After the modeling is finished, tail blood is taken to check relevant anti-helicobacter pylori antibodies, and positive results are obtained, namely the modeling is successful. 110 rats are randomly selected and divided into 11 groups, 10 rats in each group are respectively set as a model control group and each example group is respectively subjected to gastric lavage with each example group medicament (0.5 g/kg, gastric lavage dosage is 1mL/100 g), and total time of 1 time per day is 10 days, wherein the model control group is subjected to gastric lavage with equal amount of physiological saline. After fasted for 1 day after the end of administration, rats were sacrificed, gastric cavity was cut off, 3 pieces of stomach tissue were taken for gastric mucosa smear, bacterial culture and rapid urokinase test, and then the positive numbers were counted, the eradication rate was calculated with the three indexes as eradication indexes negative at the same time, and the results were recorded in table 3.
TABLE 3 Table 3
As is clear from the above table, the composition of the present invention can effectively inhibit helicobacter pylori, and under the premise of lower dosage, the eradication rate of helicobacter pylori can reach more than 90%, while the eradication rate of helicobacter pylori of comparative examples 1-5 is 20% -70%, especially the eradication rates of comparative examples 1 and 2 are the lowest, which indicates that the selection of the extraction solvent is important for the selected raw materials of the present invention to exert the effect of inhibiting helicobacter pylori. From the results of comparative examples 3 to 4, it is clear that the choice and ratio of the mixed solvent of ethanol and ethylene glycol dimethyl ether, the mixed solvent of ethanol and ethylene glycol monoethyl ether and N-N-dimethylformamide have significant differences in the results. As a result of analysis of the results of comparative example 5, the composition without the ultrafiltration membrane molecular interception treatment was 20% lower than that of example 1 in eradication rate of helicobacter pylori, indicating that the raw materials of Tribulus terrestris, berberis hard Hu Taoguo, acanthopanax sessiliflorus, echinacea, cocois pungens and Gymnema sylvestre had active ingredients having a molecular weight of mainly 30000-50000 and active ingredients having a molecular weight of 20000-50000 for inhibiting helicobacter pylori.
Finally, it should be noted that the foregoing description is only a preferred embodiment of the present invention, and the present invention is not limited to the above-mentioned embodiment, but may be modified or some of the technical features thereof may be replaced by other technical solutions described in the foregoing embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (8)
1. A composition for inhibiting helicobacter pylori is characterized by comprising the following raw materials in parts by weight: 110 to 160 parts of royal jelly, 100 to 150 parts of eucalyptus honey, 110 to 150 parts of caltrop, 100 to 150 parts of berk nut, 90 to 170 parts of acanthopanax sessiliflorus, 110 to 150 parts of purple daisy, 110 to 150 parts of lithocarpus litsea, and 90 to 170 parts of gymnema sylvestre;
the preparation of the composition comprises the following steps:
(1) Thawing Lac Regis Apis with water, mixing with Eucalyptus Mel, and lyophilizing to obtain powder;
(2) Pulverizing caltrop, berhard Hu Taoguo and acanthopanax sessiliflorus, extracting with mixed solvent of 80% -100% ethanol water solution and 45% -75% ethylene glycol dimethyl ether water solution, filtering, extracting filtrate with 60% -80% N-N-dimethylformamide water solution, separating with ultrafiltration membrane with molecular weight cut-off of 30000-50000, concentrating under reduced pressure to remove solvent, drying to obtain extract powder, wherein the volume ratio of ethanol water solution to ethylene glycol dimethyl ether water solution is (5-8): (1-3);
(3) Crushing the purple daisy, the lithocarpus litsea and the gymnema sylvestre, extracting by using a mixed solvent of an ethanol aqueous solution with the volume fraction of 80-90% and ethylene glycol monoethyl ether with the volume fraction of 30-60%, filtering, adding the filtrate into an N-N-dimethylformamide aqueous solution with the volume fraction of 60-80%, extracting, separating by using an ultrafiltration membrane with the molecular weight cutoff of 20000-50000, concentrating under reduced pressure to remove the solvent, and drying to obtain extract powder, wherein the volume ratio of the ethanol aqueous solution to the ethylene glycol monoethyl ether is (2-3): 1, a step of;
(4) Mixing the above processed powders.
2. The helicobacter pylori inhibiting composition according to claim 1, characterized by being prepared from the following raw materials in parts by weight: 120-140 parts of royal jelly, 110-140 parts of eucalyptus honey, 120-140 parts of caltrop, 120-140 parts of berk nut, 120-150 parts of acanthopanax sessiliflorus, 120-140 parts of purple daisy, 120-140 parts of lithocarpus litsea, and 130-150 parts of gymnema sylvestre.
3. The helicobacter pylori inhibiting composition according to claim 1, characterized by being prepared from the following raw materials in parts by weight: 110 to 130 parts of royal jelly, 100 to 130 parts of eucalyptus honey, 120 to 150 parts of caltrop, 120 to 150 parts of berk nut, 90 to 140 parts of acanthopanax sessiliflorus, 110 to 130 parts of purple daisy, 120 to 150 parts of lithocarpus litsea, and 130 to 170 parts of gymnema sylvestre.
4. The helicobacter pylori inhibiting composition according to claim 1, characterized by being prepared from the following raw materials in parts by weight: 130-160 parts of royal jelly, 130-150 parts of eucalyptus honey, 110-130 parts of caltrop, 100-130 parts of berk nut, 140-170 parts of acanthopanax sessiliflorus, 120-150 parts of purple daisy, 110-130 parts of lithocarpus litsea, and 90-140 parts of gymnema sylvestre.
5. The helicobacter pylori inhibiting composition according to claim 1, wherein in the step (2), the extraction feed ratio of the aqueous ethanol solution to the aqueous ethylene glycol dimethyl ether solution is 1: (6-8), the extraction temperature is 25-35 ℃, and the extraction time is 1-2 h.
6. The helicobacter pylori inhibiting composition according to claim 1, wherein in the step (3), the extraction feed ratio of the aqueous ethanol solution to the ethylene glycol monoethyl ether is 1: (6-8), the extraction temperature is 30-40 ℃ and the extraction time is 1-2 h.
7. The helicobacter pylori inhibiting composition according to claim 1, wherein in the step (2) or (3), the aqueous N-dimethylformamide extract liquid-to-liquid ratio is 1: (1.5-2.0), extracting at normal temperature for 2-3 h.
8. Use of a composition according to any one of claims 1 to 7 for the preparation of an anti-helicobacter pylori medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211629293.0A CN115804803B (en) | 2022-12-19 | 2022-12-19 | Composition for inhibiting helicobacter pylori and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211629293.0A CN115804803B (en) | 2022-12-19 | 2022-12-19 | Composition for inhibiting helicobacter pylori and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115804803A CN115804803A (en) | 2023-03-17 |
| CN115804803B true CN115804803B (en) | 2023-09-15 |
Family
ID=85486094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211629293.0A Active CN115804803B (en) | 2022-12-19 | 2022-12-19 | Composition for inhibiting helicobacter pylori and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115804803B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1981860A (en) * | 2005-12-16 | 2007-06-20 | 佛山德众药业有限公司 | Chinese-medicinal composition for treating chronic gastritis and atrophic gastritis and its production |
| CN102671190A (en) * | 2012-04-26 | 2012-09-19 | 安徽省芬格欣普蓝生物药业有限公司 | Enzymic preparations for improving human body immunity and enhancing gastrointestinal and respiratory functions |
| CN114848755A (en) * | 2022-07-06 | 2022-08-05 | 吉林华康药业股份有限公司 | Traditional Chinese medicine composition for inhibiting helicobacter pylori |
-
2022
- 2022-12-19 CN CN202211629293.0A patent/CN115804803B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1981860A (en) * | 2005-12-16 | 2007-06-20 | 佛山德众药业有限公司 | Chinese-medicinal composition for treating chronic gastritis and atrophic gastritis and its production |
| CN102671190A (en) * | 2012-04-26 | 2012-09-19 | 安徽省芬格欣普蓝生物药业有限公司 | Enzymic preparations for improving human body immunity and enhancing gastrointestinal and respiratory functions |
| CN114848755A (en) * | 2022-07-06 | 2022-08-05 | 吉林华康药业股份有限公司 | Traditional Chinese medicine composition for inhibiting helicobacter pylori |
Non-Patent Citations (1)
| Title |
|---|
| 蜂产品治疗胃部疾病作用机理探讨;姚海春;姚京辉;陈云;;中国蜂业(第10期);第41-42页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115804803A (en) | 2023-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011142618A2 (en) | Method for preparing novel processed ginseng or an extract thereof, the usually minute ginsenoside content of which is increased | |
| CN114848755B (en) | Traditional Chinese medicine composition for inhibiting helicobacter pylori | |
| CN101249259B (en) | High content and high activity oral polysaccharide-peptide and preparing method and application of the same | |
| CN104997917A (en) | Gynecological traditional Chinese medicine composition containing nano-silver | |
| CN112263586B (en) | Hesperidin-rosemary anti-diarrhea preparation as well as preparation method and application thereof | |
| CN115804803B (en) | Composition for inhibiting helicobacter pylori and preparation method thereof | |
| CN107184702B (en) | Traditional Chinese medicine composition for preventing and treating proventriculitis and myogastritis of poultry and preparation method thereof | |
| CN106177187B (en) | Tea polyphenol tea polysaccharide composition with synergistic attenuation and anti-liver cancer effects | |
| CN112535239A (en) | Compound Chinese herbal medicine feed additive for daily health care and growth promotion of livestock and preparation and application thereof | |
| CN106728038A (en) | A kind of Chinese medicine fodder pre-mixing agent for preventing and treating aquatic livestock disease in the liver and gallbladder and preparation method thereof | |
| CN108186957B (en) | Traditional Chinese medicine composition for treating poultry multi-cause respiratory system diseases and preparation method thereof | |
| CN107950814B (en) | Natural feed additive for improving immunity of aquatic animals and preparation method thereof | |
| CN115624579A (en) | Traditional Chinese medicine composition for inhibiting aeromonas veronii and application thereof | |
| CN112219864A (en) | Chinese herbal medicine antibacterial liquid and preparation method thereof | |
| CN112870246A (en) | Active substance, preparation and anti-inflammatory application thereof | |
| CN104857116A (en) | Applications of traditional Chinese medicine sanguisorba officinalis in preparing antifungal drug synergist | |
| CN111642655A (en) | Method for developing compound Chinese herbal medicine feed additive for procambarus clarkia | |
| CN116870094B (en) | Preparation method of oral liquid for clearing heat and detoxicating | |
| CN116268196B (en) | Plant source composite additive and application thereof | |
| CN115804807B (en) | Traditional Chinese medicine compound composition for preventing and treating mycoplasma ovipneumoniae and preparation method and application thereof | |
| CN115531464B (en) | Traditional Chinese medicine composition for resisting mycoplasma caprae pneumonia as well as preparation method and application thereof | |
| CN102491869B (en) | Rheumlikiangense extract with liver injury protection activity and preparation method thereof | |
| CN116270908B (en) | Application of vetiver product in preparation of medicines for improving animal immunity and resisting inflammation | |
| CN112369585B (en) | Application of gallnut honey in preparation of anti-helicobacter pylori product | |
| CN115154427B (en) | Preparation method for improving effect of Sihuang dysentery stopping particles in treating damp-heat dysentery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |